Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1624

1.

Facial nerve palsy associated with atomoxetine-induced hypertension.

Kobayashi H, Fujii K, Kobayashi M, Saito N, Okunushi K, Ebata R, Shiohama T, Sawada D, Shimojo N.

Brain Dev. 2018 Oct 9. pii: S0387-7604(18)30162-1. doi: 10.1016/j.braindev.2018.09.009. [Epub ahead of print]

PMID:
30314873
2.

Catecholaminergic manipulation alters dynamic network topology across cognitive states.

Shine JM, van den Brink RL, Hernaus D, Nieuwenhuis S, Poldrack RA.

Netw Neurosci. 2018 Sep 1;2(3):381-396. doi: 10.1162/netn_a_00042. eCollection 2018.

3.

Atomoxetine prevents working memory loss in hyperactive rats, mediating plastic changes in prefrontal cortex pyramidal neurons.

Martínez-Torres NI, González-Tapia D, Vázquez-Hernández N, González-Burgos I.

Pharmacol Biochem Behav. 2018 Sep 26;175:116-122. doi: 10.1016/j.pbb.2018.09.010. [Epub ahead of print]

PMID:
30267796
4.

Delusional infestation in the treatment of ADHD with atomoxetine.

Howes CF, Sharp C.

BMJ Case Rep. 2018 Sep 23;2018. pii: bcr-2018-226020. doi: 10.1136/bcr-2018-226020.

PMID:
30249731
5.

Therapy for fatigue and cognitive dysfunction in postural orthostatic tachycardia syndrome.

Boris JR, Bernadzikowski T.

Cardiol Young. 2018 Sep 10:1-6. doi: 10.1017/S1047951118001415. [Epub ahead of print]

PMID:
30198448
6.

Testing genetic modifiers of behavior and response to atomoxetine in autism spectrum disorder with ADHD.

Barrie ES, Pinsonneault JK, Sadee W, Hollway JA, Handen BL, Smith T, Arnold LE, Butter E, Hansen-Kiss E, Herman GE, Aman MG.

J Dev Phys Disabil. 2018 Jun;30(3):355-371. doi: 10.1007/s10882-018-9590-4. Epub 2018 Mar 5.

7.

Evaluation of Two Types of Drug Treatment with QEEG in Children with ADHD.

Aldemir R, Demirci E, Bayram AK, Canpolat M, Ozmen S, Per H, Tokmakci M.

Transl Neurosci. 2018 Sep 1;9:106-116. doi: 10.1515/tnsci-2018-0017. eCollection 2018.

8.

Systematic review of the screening, diagnosis, and management of ADHD in children with epilepsy. Consensus paper of the Task Force on Comorbidities of the ILAE Pediatric Commission.

Auvin S, Wirrell E, Donald KA, Berl M, Hartmann H, Valente KD, Van Bogaert P, Cross JH, Osawa M, Kanemura H, Aihara M, Guerreiro MM, Samia P, Vinayan KP, Smith ML, Carmant L, Kerr M, Hermann B, Dunn D, Wilmshurst JM.

Epilepsia. 2018 Sep 3. doi: 10.1111/epi.14549. [Epub ahead of print]

PMID:
30178479
9.

Management of Attention-Deficit Disorder and Attention-Deficit/Hyperactivity Disorder Drug Intoxication in Dogs and Cats: An Update.

Stern L, Schell M.

Vet Clin North Am Small Anim Pract. 2018 Aug 29. pii: S0195-5616(18)30086-X. doi: 10.1016/j.cvsm.2018.07.007. [Epub ahead of print] Review.

PMID:
30172446
10.

Asymmetric Synthesis of α,β-Unsaturated δ-Lactones through Copper(I)-Catalyzed Direct Vinylogous Aldol Reaction.

Zhang HJ, Yin L.

J Am Chem Soc. 2018 Sep 26;140(38):12270-12279. doi: 10.1021/jacs.8b07929. Epub 2018 Sep 11.

PMID:
30157644
11.

The Effect of Methylphenidate and Atomoxetine on Heart Rate and Systolic Blood Pressure in Young People and Adults with Attention-Deficit Hyperactivity Disorder (ADHD): Systematic Review, Meta-Analysis, and Meta-Regression.

Liang EF, Lim SZ, Tam WW, Ho CS, Zhang MW, McIntyre RS, Ho RC.

Int J Environ Res Public Health. 2018 Aug 20;15(8). pii: E1789. doi: 10.3390/ijerph15081789. Review.

12.

Antihyperalgesic Activity of Atomoxetine on Diabetes-Induced Neuropathic Pain: Contribution of Noradrenergic and Dopaminergic Systems.

Barbaros MB, Can ÖD, Üçel Uİ, Turan Yücel N, Demir Özkay Ü.

Molecules. 2018 Aug 19;23(8). pii: E2072. doi: 10.3390/molecules23082072.

13.

The Atxn7-overexpressing mice showed hyperactivity and impulsivity which were ameliorated by atomoxetine treatment: A possible animal model of the hyperactive-impulsive phenotype of ADHD.

Dela Peña IJI, Botanas CJ, de la Peña JB, Custodio RJ, Dela Peña I, Ryoo ZY, Kim BN, Ryu JH, Kim HJ, Cheong JH.

Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jan 10;88:311-319. doi: 10.1016/j.pnpbp.2018.08.012. Epub 2018 Aug 17.

PMID:
30125623
14.

[Supervised off-label prescribing of methylphenidate in adult ADHD].

Carton L, Dondaine T, Deheul S, Marquié C, Brigadeau F, Amad A, Devos D, Danel T, Bordet R, Cottencin O, Gautier S, Ménard O.

Encephale. 2018 Aug 16. pii: S0013-7006(18)30092-7. doi: 10.1016/j.encep.2018.05.008. [Epub ahead of print] French.

PMID:
30122296
15.

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.

Kim SH, Byeon JY, Kim YH, Lee CM, Lee YJ, Jang CG, Lee SY.

Sci Rep. 2018 Aug 17;8(1):12405. doi: 10.1038/s41598-018-30841-8.

16.

Update on Common Psychiatric Medications for Children.

Sharma A.

Pediatr Ann. 2018 Aug 1;47(8):e311-e316. doi: 10.3928/19382359-20180702-01. Review.

PMID:
30102754
17.

Incidence of Heart Failure and Cardiomyopathy Following Initiation of Medications for Attention-Deficit/Hyperactivity Disorder: A Descriptive Study.

Mosholder AD, Taylor L, Mannheim G, Ortendahl L, Woodworth TS, Toh S.

J Clin Psychopharmacol. 2018 Oct;38(5):505-508. doi: 10.1097/JCP.0000000000000939.

PMID:
30102629
18.

Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.

Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A.

Lancet Psychiatry. 2018 Sep;5(9):727-738. doi: 10.1016/S2215-0366(18)30269-4. Epub 2018 Aug 7.

19.

Amplification and Suppression of Distinct Brainwide Activity Patterns by Catecholamines.

van den Brink RL, Nieuwenhuis S, Donner TH.

J Neurosci. 2018 Aug 22;38(34):7476-7491. doi: 10.1523/JNEUROSCI.0514-18.2018. Epub 2018 Jul 23.

20.

Atomoxetine.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Supplemental Content

Loading ...
Support Center